Published in Cancer Weekly, June 19th, 2006
"I-131-MIBG and Y-90-DOTATOC have been used as radiotherapeutic agents for treating neuroenclocrine tumors. The tumor dose delivered by these agents is often insufficient to control or cure the disease," researchers in the United States reported.
"However, these 2 agents used together could potentially increase tumor dose without exceeding the critical organ dose because the dose-limiting tissues are different," explained M.T. Madsen and colleagues, University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.